When a hospital recognises an outbreak of a multidrug-resistant organism (MDRO), such as carbapenem-resistant Klebsiella, Acinetobacter, MRSA, VRE or Candida auris, the first cases have usually been in the data for days or weeks. The isolates were reported. They simply were not connected in time.
Earlier detection does not mean software "preventing" outbreaks. It means giving infection prevention teams the right signal sooner, so their expertise, through investigation, isolation, cohorting and environmental review, can be applied while the cluster is still small.
Why clusters are missed
- Fragmented data: isolates sit in the LIS, admissions and transfers sit in the HMIS, and IPC notes sit in registers. Nobody sees all three together.
- Movement of patients: a cluster spread across an ICU, a step-down unit and a surgical ward looks like three unrelated cases.
- Low baseline thinking: two or three cases of a common organism do not feel unusual unless you know the expected rate for that unit and period.
- Delays: weekly or monthly line lists are too slow for organisms that spread within days.
Evidence that systematic detection works
Automated statistical cluster detection on routine microbiology data has a long track record in research. In a 2010 PLoS Medicine study, WHONET-SaTScan applied to five years of microbiology data from a 750-bed US academic hospital identified 59 clusters. Hospital epidemiologists judged more than 95% worth considering and 27% as warranting active investigation or intervention, and the method found MRSA and VRE clusters that routine surveillance had missed. More recent regional work, including studies of rare resistant species, continues to support automated detection as a complement to expert review.
The lesson is that the signal is there. Hospitals need a reliable way to surface it.
A practical early-detection approach
1. Define your alert organisms and phenotypes
Agree, through the HICC, which organisms and resistance phenotypes trigger immediate notification, for example carbapenem resistance in Enterobacterales, MRSA, VRE, C. auris, and isolates flagged MDR, XDR or PDR. Apply consistent definitions so that flags mean the same thing every time.
2. Notify in real time
Every alert organism should reach the duty infection control nurse the same day it is reported, so that contact precautions and screening can start immediately.
3. Distinguish hospital-onset from community-onset
Use specimen date relative to admission (for example, specimens collected on or after day 3 of admission) to separate likely hospital-onset cases. A rising hospital-onset share is a strong warning sign.
4. Watch trends by unit and time
Compare current counts against each unit's baseline. Unit-level antibiograms and resistance trend charts reveal gradual shifts, such as falling carbapenem susceptibility, that a single isolate never would.
5. Add epidemiological context
Link cases by ward, bed, overlapping stays, shared procedures or devices. Where available, molecular typing confirms relatedness, but epidemiological links often justify action before typing results arrive.
6. Escalate and track
A suspected cluster should open a tracked investigation with an owner, actions (screening, cohorting, enhanced cleaning, staff education) and a close-out review at the HICC.
Why it matters in India
The ICMR AMRSN 2024 report, drawing on close to 100,000 isolates from tertiary-care centres, continues to document high resistance in priority Gram-negative pathogens. Research in The Lancet Regional Health – Southeast Asia found carbapenem resistance in hospital-acquired Klebsiella bloodstream infections rising ahead of community-acquired ones. Hospitals are a key place where resistance amplifies, and therefore a key place to detect it early.
Why hospitals choose Ibhar
Ibhar helps hospitals spot resistant organisms and emerging trends sooner, so IPC teams can act before transmission spreads. Ibhar is the infection intelligence platform for infection prevention and control (IPC), antimicrobial stewardship (AMS) and antimicrobial resistance (AMR). Hospitals from India to the Middle East use it, and it works alongside Epic, Oracle Health (Cerner) and InterSystems.
- 800+ hospitals with Ibhar implementation experience.
- Technology partner to the JIPMER-led national antibiogram study across 75+ hospitals.
- Around 500,000 positive culture records analysed.
To see what Ibhar could do for your hospital, talk to our team.